Investigational Treatment
Phase 3Small molecule
NovartisInvestigational Treatment is one of 133 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 3.
4
Indications
5
Total Trials
0
Active Trials
132
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
221 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Briviact
UCBPhase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Dayvigo
EisaiPhase 3
Depacon
AbbViePhase 3
Zonegran
AAzurity Pharmaceuticals
Phase 3
Actemra
RochePhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
GWP42003-P
Jazz PharmaceuticalsPhase 3
Immunoglobulin
SanofiPhase 3
Lamictal
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Alcoholic Fatty Liver Disease1 trial
Epilepsy1 trial
Seizure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Investigational Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]